Fluoxetine: Difference between revisions
mNo edit summary |
m (Reverted edits by Ethanael270454 (talk) to last revision by NNethala) |
||
| Line 6: | Line 6: | ||
==Dosing and Administration== | ==Dosing and Administration== | ||
'''Major Depressive Disorder'''<br> | '''Major Depressive Disorder'''<br> | ||
Adult | Adult — In controlled trials used to support the efficacy of fluoxetine, patients were administered morning doses ranging from 20 to 80 mg/day. | ||
Studies comparing fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in major | Studies comparing fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in major | ||
depressive disorder in most cases. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. | depressive disorder in most cases. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. | ||
| Line 14: | Line 14: | ||
<br> | <br> | ||
'''Obsessive-Compulsive Disorder'''<br> | '''Obsessive-Compulsive Disorder'''<br> | ||
Adult | Adult — In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered fixed daily | ||
doses of 20, 40, or 60 mg of fluoxetine or placebo. In 1 of these studies, no dose-response relationship for effectiveness was | doses of 20, 40, or 60 mg of fluoxetine or placebo. In 1 of these studies, no dose-response relationship for effectiveness was | ||
demonstrated. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Since there was a suggestion of | demonstrated. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Since there was a suggestion of | ||
| Line 38: | Line 38: | ||
<br> | <br> | ||
<br> | <br> | ||
For more detailed information on dosing please refer to [ | For more detailed information on dosing please refer to [[Fluoxetine instructions for administration| Instructions for administration]] | ||
<br> | <br> | ||
<br> | <br> | ||
| Line 44: | Line 44: | ||
<br> | <br> | ||
<font size="4"> | <font size="4"> | ||
[ | [[{{PAGENAME}}#FDA Package Insert Resources|FDA Package Insert Resources]] | ||
<br></font size><small>Indications, Contraindications, Side Effects, Drug Interactions, etc.</small><font size="4"><br> | <br></font size><small>Indications, Contraindications, Side Effects, Drug Interactions, etc.</small><font size="4"><br> | ||
<br> | <br> | ||
[http:// | [http://www.pace-med-apps.com/gfrcalc.htm Calculate Creatine Clearance] | ||
<br></font size><small>On line calculator of your patients Cr Cl by a variety of formulas.</small><font size="4"><br> | <br></font size><small>On line calculator of your patients Cr Cl by a variety of formulas.</small><font size="4"><br> | ||
<br> | <br> | ||
[http:// | [http://home.earthlink.net/~sensei11/convert.htm Convert pounds to Kilograms] | ||
<br></font size><small>On line calculator of your patients weight in pounds to Kg for dosing estimates.</small><font size="4"><br> | <br></font size><small>On line calculator of your patients weight in pounds to Kg for dosing estimates.</small><font size="4"><br> | ||
<br> [ | <br> [[{{PAGENAME}}#Publication Resources|Publication Resources]] | ||
<br></font size><small>Recent articles, WikiDoc State of the Art Review, Textbook Information</small><font size="4"><br> | <br></font size><small>Recent articles, WikiDoc State of the Art Review, Textbook Information</small><font size="4"><br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}}#Trial Resources|Trial Resources]] | ||
<br></font size><small>Ongoing Trials, Trial Results</small><font size="4"><br> | <br></font size><small>Ongoing Trials, Trial Results</small><font size="4"><br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}}#Guidelines & Evidence Based Medicine Resources|Guidelines & Evidence Based Medicine Resources]] | ||
<br></font size><small>US National Guidelines, Cochrane Collaboration, etc.</small><font size="4"><br> | <br></font size><small>US National Guidelines, Cochrane Collaboration, etc.</small><font size="4"><br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}}#Media Resources|Media Resources]] | ||
<br></font size><small>Slides, Video, Images, MP3, Podcasts, etc.</small><font size="4"><br><br> | <br></font size><small>Slides, Video, Images, MP3, Podcasts, etc.</small><font size="4"><br><br> | ||
[ | [[{{PAGENAME}}#Patient Resources|Patient Resources]] | ||
<br></font size><small>Discussion Groups, Handouts, Blogs, News, etc.</small><font size="4"><br> | <br></font size><small>Discussion Groups, Handouts, Blogs, News, etc.</small><font size="4"><br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}}#International Resources|International Resources]] | ||
<br></font size><small>en | <br></font size><small>en Español</small><font size="4"><br> | ||
<br> | <br> | ||
---- | ---- | ||
| Line 76: | Line 76: | ||
==FDA Package Insert Resources== | ==FDA Package Insert Resources== | ||
[ | [[{{PAGENAME}} indications|Indications]] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}} contraindications|Contraindications]] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}} side effects|Side Effects]] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}} drug interactions|Drug Interactions]] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}} precautions|Precautions]] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}} overdose|Overdose]] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}} instructions for administration|Instructions for Administration]] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}} how supplied|How Supplied]] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[{{PAGENAME}} pharmacokinetics and molecular data|Pharmacokinetics and Molecular Data]] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.fda.gov/medwatch/SAFETY/2004/aug_PI/Prozac_PI.pdf FDA label] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
</font size><small>[ | </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4"> | ||
<br> | <br> | ||
<br> | <br> | ||
==Publication Resources== | ==Publication Resources== | ||
[http:// | [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most Recent Articles on {{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D Review Articles on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28%28N+Engl+J+Med%5Bta%5D%29+OR+%28Lancet%5Bta%5D%29+OR+%28BMJ%5Bta%5D%29%29 Articles on {{PAGENAME}} in N Eng J Med, Lancet, BMJ] | ||
<br> | <br> | ||
<br> | <br> | ||
[ | [[WikiDoc state of the art review on {{PAGENAME}}|WikiDoc State of the Art Review]] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://books.google.com/books?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=gp Textbook Information on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
</font size><small>[ | </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4"> | ||
<br> | <br> | ||
<br> | <br> | ||
==Trial Resources== | ==Trial Resources== | ||
[http:// | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials with {{PAGENAME}} at Clinical Trials.gov] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28randomized+controlled+trial%5BPublication+Type%5D+OR+%28randomized%5BTitle%2FAbstract%5D+AND+controlled%5BTitle%2FAbstract%5D+AND+trial%5BTitle%2FAbstract%5D%29%29 Trial Results with {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
</font size><small>[ | </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4"> | ||
<br> | <br> | ||
<br> | <br> | ||
==Guidelines & Evidence Based Medicine Resources== | ==Guidelines & Evidence Based Medicine Resources== | ||
[http:// | [http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cochrane Database Syst Rev[ta])}} Cochrane Collaboration on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cost effectiveness)}} Cost Effectiveness of {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
</font size><small>[ | </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4"> | ||
<br> | <br> | ||
<br> | <br> | ||
==Media Resources== | ==Media Resources== | ||
[http:// | [http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint Slides on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images of {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=hPo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+podcasts+OR+MP3&btnG=Search Podcasts & MP3s on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://video.google.com/videosearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&um=1&sa=N&tab=fv# Videos on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
</font size><small>[ | </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4"> | ||
<br> | <br> | ||
<br> | <br> | ||
==Patient Resources== | ==Patient Resources== | ||
[ | [[{{PAGENAME}} (patient information)|Patient Information from National Library of Medicine]] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.google.com/search?hl=en&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:for_patients&cx=disease_for_patients&sa=N&oi=cooptsr&resnum=0&ct=col3&cd=1 Patient Resources on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://groups.google.com/groups/search?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search Discussion Groups on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:patient_handouts&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col1&cd=3 Patient Handouts on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the News] | ||
<br> | <br> | ||
<br> | <br> | ||
[http:// | [http://finance.google.com/finance?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=te {{PAGENAME}} in the Marketplace] | ||
<br> | <br> | ||
<br> | <br> | ||
</font size><small>[ | </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4"> | ||
<br> | <br> | ||
<br> | <br> | ||
==International Resources== | ==International Resources== | ||
[http:// | [http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+en+espanol&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a {{PAGENAME}} en Español] | ||
<br> | <br> | ||
<br> | <br> | ||
</font size><small>[ | </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4"> | ||
<br> | <br> | ||
<br> | <br> | ||
Revision as of 04:14, 25 September 2011
Synonyms / Brand Names: Fluoxetinum, Fluoxetine Hydrochloride, Fluoxetine Hcl, Fluoxetina, Fluoxetina, Animex-On, Deprex, Eufor, Fluctin, Fluoxeren, Fluval, Fontex, Foxetin, Portal, Prozac, Prozac Weekly, Pulvules, Reneuron, Sarafem, Adofen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Dosing and Administration
Major Depressive Disorder
Adult — In controlled trials used to support the efficacy of fluoxetine, patients were administered morning doses ranging from 20 to 80 mg/day.
Studies comparing fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in major
depressive disorder in most cases. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose.
A dose increase may be considered after several weeks if insufficient clinical improvement is observed. Doses above 20 mg/day may be
administered on a once-a-day (morning) or BID schedule (i.e., morning and noon) and should not exceed a maximum dose of 80 mg/day.
Obsessive-Compulsive Disorder
Adult — In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered fixed daily
doses of 20, 40, or 60 mg of fluoxetine or placebo. In 1 of these studies, no dose-response relationship for effectiveness was
demonstrated. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Since there was a suggestion of
a possible dose-response relationship for effectiveness in the second study, a dose increase may be considered after several weeks if insufficient
clinical improvement is observed. The full therapeutic effect may be delayed until 5 weeks of treatment or longer.
Doses above 20 mg/day may be administered on a once-a-day (i.e., morning) or BID schedule (i.e., morning and noon). A dose range of 20 to
60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD. The maximum fluoxetine dose
should not exceed 80 mg/day.
Bulimia Nervosa
In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of bulimia nervosa, patients were administered fixed daily
fluoxetine doses of 20 or 60 mg, or placebo. Only the 60-mg dose was statistically significantly superior to placebo in
reducing the frequency of binge-eating and vomiting. Consequently, the recommended dose is 60 mg/day, administered in the morning. For some
patients it may be advisable to titrate up to this target dose over several days. Fluoxetine doses above 60 mg/day have not been systematically
studied in patients with bulimia.
Panic Disorder
In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of panic disorder, patients were administered fluoxetine
doses in the range of 10 to 60 mg/day. Treatment should be initiated with a dose of 10 mg/day. After 1 week, the dose should
be increased to 20 mg/day. The most frequently administered dose in the 2 flexible-dose clinical trials was 20 mg/day.
For more detailed information on dosing please refer to Instructions for administration
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Fluoxetine
Return to top
Publication Resources
Most Recent Articles on Fluoxetine
Review Articles on Fluoxetine
Articles on Fluoxetine in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Fluoxetine
Return to top
Trial Resources
Ongoing Trials with Fluoxetine at Clinical Trials.gov
Trial Results with Fluoxetine
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Fluoxetine
Cochrane Collaboration on Fluoxetine
Cost Effectiveness of Fluoxetine
Return to top
Media Resources
Powerpoint Slides on Fluoxetine
Images of Fluoxetine
Podcasts & MP3s on Fluoxetine
Videos on Fluoxetine
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Fluoxetine
Discussion Groups on Fluoxetine
Patient Handouts on Fluoxetine
Blogs on Fluoxetine
Fluoxetine in the News
Fluoxetine in the Marketplace
Return to top
International Resources
Fluoxetine en Español
Return to top
Adapted from the FDA Package Insert.